Bladder cancer treatment remains a challenge to every oncologist. We
report the case of a 57-year-old man with BCG-refractory bladder cancer,
who had a complete response to the intravesical Gemcitabine to shine the
light on the role of Gemcitabine as a bladder sparing treatment in
BCG-failure patients.